Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
Clinical trial NCT02415127 · COMPLETED
Trial details
- NCT number
- NCT02415127
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-01
- Primary completion
- 2016-11-01
- Enrollment
- 92
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.